CoChat

Multi-Omic analyses characterize the ceramide/sphingomyelin pathway as a therapeutic target in Alzheimer’s disease

Open access
Baloni, Priyanka, Arnold, Matthias, Buitrago, Luna, Nho, Kwangsik, Moreno, Herman, Huynh, Kevin, Brauner, Barbara, Louie, Gregory, Kueider-Paisley, Alexandra, Suhre, Karsten, Saykin, Andrew J., Ekroos, Kim, Meikle, Peter J., Hood, Leroy, Price, Nathan D., The Alzheimer’s Disease Metabolomics Consortium, Arnold, Matthias, Blach, Colette, Kaddurah-Daouk, Rima, Doraiswamy, Murali, Mahmoudiandehkordi, Siamak, Welsh-Bohmer, Kathleen, Plassman, Brenda, Krumsiek, Jan, Batra, Richa, Saykin, Andrew, Yan, Jingwen, Risacher, Shannon L., Meikle, Peter, Wang, Tingting, Ikram, Arfan, Ahmad, Shahzad, Hankemeier, Thomas, Hernandez, Ivan A., Heinken, Almut, Martinelli, Filippo, Thiele, Ines, Hertel, Johannes, Hensen, Tim, Hulshof, Tim, Farrer, Lindsay A., Au, Rhoda, Qiu, Wendy Wei Qiao, Stein, Thor, Karu, Naama, Borkowski, Kamil, Newman, John, Jia, Wei, Xie, Guoxiang, Wang, Jingye, Wei, Runmin, Rader, Dan, Kling, Mitchel, Shaw, Leslie, Doraiswamy, P. Murali, Funk, Cory C., Hernández, A. Iván, Kastenmüller, Gabi, Baillie, Rebecca, Han, Xianlin, Kaddurah-Daouk, Rima · 2022 · Communications Biology
Cited by 111

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Dysregulation of sphingomyelin and ceramide metabolism have been implicated in Alzheimer’s disease. Genome-wide and transcriptome-wide association studies have identified various genes and genetic variants in lipid metabolism that are associated with Alzheimer’s disease. However, the molecular mechanisms of sphingomyelin and ceramide disruption remain to be determined. We focus on the sphingolipid pathway and carry out multi-omics analyses to identify central and peripheral metabolic changes in Alzheimer’s patients, correlating them to imaging features. Our multi-omics approach is based on (a) 2114 human post-mortem brain transcriptomics to identify differentially expressed genes; (b) in silico metabolic flux analysis on context-specific metabolic networks identified differential reaction fluxes; (c) multimodal neuroimaging analysis on 1576 participants to associate genetic variants in sphingomyelin pathway with Alzheimer’s disease pathogenesis; (d) plasma metabolomic and lipidomic analysis to identify associations of lipid species with dysregulation in Alzheimer’s; and (e) metabolite genome-wide association studies to define receptors within the pathway as a potential drug target. We validate our hypothesis in amyloidogenic APP/PS1 mice and show prolonged exposure to fingolimod alleviated synaptic plasticity and cognitive impairment in mice. Our integrative multi-omics approach identifies potential targets in the sphingomyelin pathway and suggests modulators of S1P metabolism as possible candidates for Alzheimer’s disease treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42003-022-04011-6

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 111

Metadata

Authors
Baloni, P., Arnold, M., Buitrago, L., Nho, K., Moreno, H., Huynh, K., Brauner, B., Louie, G., Kueider-Paisley, A., Suhre, K., Saykin, A. J., Ekroos, K., Meikle, P. J., Hood, L., Price, N. D., The Alzheimer’s Disease Metabolomics Consortium, Arnold, M., Blach, C., Kaddurah-Daouk, R., Doraiswamy, M., Mahmoudiandehkordi, S., Welsh-Bohmer, K., Plassman, B., Krumsiek, J., Batra, R., Saykin, A., Yan, J., Risacher, S. L., Meikle, P., Wang, T., Ikram, A., Ahmad, S., Hankemeier, T., Hernandez, I. A., Heinken, A., Martinelli, F., Thiele, I., Hertel, J., Hensen, T., Hulshof, T., Farrer, L. A., Au, R., Qiu, W. W. Q., Stein, T., Karu, N., Borkowski, K., Newman, J., Jia, W., Xie, G., Wang, J., Wei, R., Rader, D., Kling, M., Shaw, L., Doraiswamy, P. M., Funk, C. C., Hernández, A. I., Kastenmüller, G., Baillie, R., Han, X., & Kaddurah-Daouk, R.
Venue
Communications Biology
Published
2022-10-08
Volume
5
Issue
1
Pages
1074-1074
ISSN
2399-3642 (ISSN-L)
OpenAlex
W4303628848
Cited by
111
References
42
FWCI
5.73
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multi-Omic analyses characterize the ceramide/sphingomyelin pathway as a therapeutic target in Alzheimer’s disease. https://app.cochat.ai/papers/10.1038/s42003-022-04011-6
The paper
Baloni, P., Arnold, M., Buitrago, L., Nho, K., Moreno, H., Huynh, K., Brauner, B., Louie, G., Kueider-Paisley, A., Suhre, K., Saykin, A. J., Ekroos, K., Meikle, P. J., Hood, L., Price, N. D., The Alzheimer’s Disease Metabolomics Consortium, Arnold, M., Blach, C., Kaddurah-Daouk, R., . . . Kaddurah-Daouk, R. (2022). Multi-Omic analyses characterize the ceramide/sphingomyelin pathway as a therapeutic target in Alzheimer’s disease. Communications Biology. https://doi.org/10.1038/s42003-022-04011-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.